Kyverna Therapeutics, Inc. (KYTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
Kyverna Therapeutics maintains a "Strong Buy" rating, driven by positive clinical data and upcoming regulatory milestones for miv-cel. Miv-cel achieved statistically significant endpoints in SPS and demonstrated deep, durable responses in gMG, with 100% of patients off chronic immunosuppression at 24 weeks. A BLA filing for SPS is expected in 1H 2026, with additional data from gMG, RA, and PMS programs anticipated as expansion catalysts.
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Kyverna Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 222,929 | $1.78M | $1.74M | -$33,330.15 | -1.88% |
| BB Bryan Buchert Kera Capital Partners Inc. | 132,603 | $465,191.26 | $1.04M | $571,764.2 | 122.91% |
| PLC Peapod Lane Capital LLC Peapod Lane Capital LLC | 40,404 | $78,597.69 | $315,959.28 | $237,361.59 | 302% |
| FDW Fourth Dimension Wealth LLC Fourth Dimension Wealth LLC | 250 | $935 | $1,955 | $1,020 | 109.09% |
| GFM GF Fund Management Co. Ltd. GF Fund Management Co. Ltd. | 977 | $3,928.98 | $7,640.14 | $3,711.16 | 94.46% |
Kyverna Therapeutics, Inc. (KYTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kyverna Therapeutics, Inc. ever had a stock split?
Kyverna Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Warner Biddle CEO | NASDAQ (NGS) Exchange | 501976104 CUSIP |
| US Country | 112 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel cell therapies for patients suffering from autoimmune diseases. The company, originally known as BAIT Therapeutics, Inc., was rebranded to Kyverna Therapeutics in October 2019 and was established in 2018. Based in Emeryville, California, Kyverna is leveraging its expertise in cell therapy to address a range of autoimmune conditions. Through strategic partnerships and licensing agreements with industry leaders such as Intellia Therapeutics, Inc. and Kite, Kyverna is advancing its mission to transform the treatment landscape for autoimmune diseases. These collaborations are aimed at the research and development of innovative CAR T-cell therapy products for autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.
Products and Services
- KYV-101
- KYV-201
- Further Product Development
An autologous CD19 CAR T-cell therapy, KYV-101 is at the forefront of Kyverna Therapeutics’ product pipeline. Designed to treat autoimmune diseases such as lupus nephritis and systemic sclerosis, KYV-101 is currently undergoing a Phase I clinical trial. Additionally, its therapeutic potential is being evaluated in Phase II clinical trials for myasthenia gravis and multiple sclerosis. By targeting CD19, a protein expressed on the surface of certain cells of the immune system, KYV-101 aims to offer a new therapeutic approach for patients with these debilitating conditions.
This allogeneic CD19 CAR T-cell product candidate represents Kyverna Therapeutics’ venture into off-the-shelf cell therapy solutions. KYV-201 is in the preclinical stage and targets multiple autoimmune diseases. The development of allogeneic CAR T-cell therapies like KYV-201 could significantly broaden the accessibility and reduce the time-to-treatment for patients, contrasting with the more personalized autologous CAR T-cell therapies that require cell customization for each patient.
In addition to KYV-101 and KYV-201, Kyverna Therapeutics is exploring the potential of CAR T-cell and other cell therapy approaches for a range of other autoimmune diseases, such as inflammatory bowel disease, which encompasses Crohn's disease and ulcerative colitis. These endeavors are part of Kyverna’s broader mission to discover and develop transformative treatments for autoimmune diseases, leveraging its platform and expertise in cell therapy to address unmet medical needs.
